| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 22 | 2021 | 374 | 4.050 |
Why?
|
| Natural Language Processing | 2 | 2023 | 37 | 1.570 |
Why?
|
| Neoplasms | 13 | 2024 | 2898 | 1.570 |
Why?
|
| Medical Oncology | 7 | 2024 | 359 | 1.530 |
Why?
|
| Medical Informatics | 4 | 2021 | 47 | 1.210 |
Why?
|
| Electronic Health Records | 4 | 2019 | 319 | 1.100 |
Why?
|
| Databases, Factual | 5 | 2022 | 814 | 1.080 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2015 | 371 | 0.940 |
Why?
|
| Software | 4 | 2019 | 654 | 0.900 |
Why?
|
| Child | 26 | 2024 | 6927 | 0.880 |
Why?
|
| Pathology, Molecular | 2 | 2019 | 34 | 0.850 |
Why?
|
| Leukemia | 1 | 2023 | 320 | 0.780 |
Why?
|
| Research Report | 2 | 2021 | 44 | 0.740 |
Why?
|
| Heuristics | 1 | 2019 | 15 | 0.700 |
Why?
|
| Radionuclide Imaging | 2 | 2021 | 220 | 0.690 |
Why?
|
| Pediatrics | 3 | 2021 | 344 | 0.680 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 1169 | 0.620 |
Why?
|
| Information Dissemination | 5 | 2024 | 103 | 0.600 |
Why?
|
| Gene Expression Profiling | 3 | 2013 | 1384 | 0.590 |
Why?
|
| Hospital Units | 1 | 2016 | 30 | 0.590 |
Why?
|
| Biomedical Research | 2 | 2021 | 376 | 0.580 |
Why?
|
| Emergencies | 1 | 2016 | 113 | 0.560 |
Why?
|
| Biomarkers, Tumor | 5 | 2022 | 1464 | 0.560 |
Why?
|
| Management Information Systems | 1 | 2016 | 3 | 0.560 |
Why?
|
| Telemedicine | 1 | 2018 | 169 | 0.550 |
Why?
|
| Patient Transfer | 1 | 2016 | 91 | 0.550 |
Why?
|
| Humans | 60 | 2024 | 86643 | 0.540 |
Why?
|
| Pressure Ulcer | 1 | 2016 | 42 | 0.530 |
Why?
|
| Infant | 15 | 2022 | 3046 | 0.500 |
Why?
|
| Polysaccharides | 1 | 2015 | 89 | 0.500 |
Why?
|
| Patient Care Team | 1 | 2016 | 280 | 0.490 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 663 | 0.470 |
Why?
|
| Critical Care | 1 | 2016 | 370 | 0.460 |
Why?
|
| Paired Box Transcription Factors | 1 | 2013 | 50 | 0.460 |
Why?
|
| Heart Arrest | 1 | 2016 | 265 | 0.460 |
Why?
|
| Lysine | 2 | 2011 | 147 | 0.440 |
Why?
|
| Proteomics | 5 | 2016 | 212 | 0.440 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 3 | 2001 | 9 | 0.430 |
Why?
|
| Rhabdomyosarcoma | 2 | 2022 | 40 | 0.430 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 166 | 0.430 |
Why?
|
| Algorithms | 4 | 2019 | 1830 | 0.420 |
Why?
|
| Oxidoreductases | 3 | 2001 | 112 | 0.420 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2022 | 127 | 0.400 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2022 | 47 | 0.390 |
Why?
|
| Adolescent | 15 | 2023 | 8981 | 0.380 |
Why?
|
| 3-Iodobenzylguanidine | 2 | 2021 | 19 | 0.380 |
Why?
|
| Loss of Heterozygosity | 2 | 2014 | 85 | 0.370 |
Why?
|
| Machine Learning | 3 | 2022 | 232 | 0.370 |
Why?
|
| Child, Preschool | 12 | 2022 | 3612 | 0.360 |
Why?
|
| Pharmacogenetics | 3 | 2019 | 434 | 0.360 |
Why?
|
| Computational Biology | 2 | 2015 | 528 | 0.350 |
Why?
|
| Isotope Labeling | 1 | 2009 | 51 | 0.350 |
Why?
|
| Databases, Protein | 1 | 2009 | 52 | 0.340 |
Why?
|
| Young Adult | 11 | 2023 | 5976 | 0.310 |
Why?
|
| N-Myc Proto-Oncogene Protein | 3 | 2017 | 36 | 0.310 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 2357 | 0.310 |
Why?
|
| Age Factors | 4 | 2021 | 1851 | 0.300 |
Why?
|
| Cohort Studies | 9 | 2021 | 2767 | 0.300 |
Why?
|
| Patient-Centered Care | 2 | 2023 | 203 | 0.300 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 456 | 0.290 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2705 | 0.260 |
Why?
|
| Acyl Coenzyme A | 2 | 2001 | 17 | 0.250 |
Why?
|
| Gene Amplification | 2 | 2017 | 131 | 0.250 |
Why?
|
| Proteins | 1 | 2009 | 777 | 0.230 |
Why?
|
| Eligibility Determination | 1 | 2023 | 32 | 0.230 |
Why?
|
| Oncogene Proteins | 2 | 2015 | 59 | 0.230 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 2 | 2000 | 11 | 0.230 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 252 | 0.230 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1920 | 0.220 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 1621 | 0.220 |
Why?
|
| Mutation | 4 | 2015 | 3968 | 0.220 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 6 | 0.220 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2022 | 47 | 0.220 |
Why?
|
| Genomics | 4 | 2022 | 720 | 0.210 |
Why?
|
| Chromatography, Liquid | 2 | 2015 | 104 | 0.210 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 2426 | 0.200 |
Why?
|
| Prognosis | 8 | 2021 | 3679 | 0.200 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 76 | 0.200 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 307 | 0.200 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 105 | 0.200 |
Why?
|
| Data Collection | 2 | 2023 | 372 | 0.200 |
Why?
|
| Arginine | 1 | 2001 | 136 | 0.200 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 1939 | 0.200 |
Why?
|
| User-Computer Interface | 2 | 2019 | 185 | 0.200 |
Why?
|
| Male | 15 | 2022 | 40965 | 0.190 |
Why?
|
| Substrate Specificity | 1 | 2001 | 347 | 0.190 |
Why?
|
| Female | 16 | 2021 | 44532 | 0.190 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.190 |
Why?
|
| Sarcoma | 1 | 2022 | 215 | 0.190 |
Why?
|
| Survivorship | 1 | 2020 | 18 | 0.180 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 21 | 0.180 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 103 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1313 | 0.180 |
Why?
|
| Myeloablative Agonists | 2 | 2016 | 34 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 2438 | 0.170 |
Why?
|
| Patient Selection | 1 | 2023 | 685 | 0.170 |
Why?
|
| Adult | 10 | 2022 | 25648 | 0.170 |
Why?
|
| Remote Sensing Technology | 1 | 2018 | 5 | 0.170 |
Why?
|
| Workflow | 1 | 2019 | 77 | 0.170 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 689 | 0.170 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 696 | 0.170 |
Why?
|
| Biomedical Technology | 1 | 2018 | 20 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 298 | 0.170 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 97 | 0.170 |
Why?
|
| Research | 1 | 2020 | 253 | 0.170 |
Why?
|
| Wearable Electronic Devices | 1 | 2018 | 23 | 0.170 |
Why?
|
| Smartphone | 1 | 2018 | 36 | 0.160 |
Why?
|
| Database Management Systems | 1 | 2018 | 41 | 0.160 |
Why?
|
| Survivors | 2 | 2016 | 226 | 0.160 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 418 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 180 | 0.150 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 25 | 0.150 |
Why?
|
| Coronary Care Units | 1 | 2016 | 4 | 0.150 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2016 | 35 | 0.140 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 45 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2021 | 1538 | 0.140 |
Why?
|
| Buthionine Sulfoximine | 1 | 2016 | 7 | 0.140 |
Why?
|
| Mitochondria | 1 | 2000 | 535 | 0.140 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 141 | 0.140 |
Why?
|
| Registries | 1 | 2020 | 702 | 0.140 |
Why?
|
| Caspase 10 | 1 | 2015 | 5 | 0.140 |
Why?
|
| Melphalan | 1 | 2016 | 98 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 141 | 0.140 |
Why?
|
| Hydrazines | 1 | 2015 | 30 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2021 | 629 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 74 | 0.140 |
Why?
|
| Risk Factors | 7 | 2021 | 5417 | 0.130 |
Why?
|
| Proteome | 1 | 2016 | 124 | 0.130 |
Why?
|
| Carbohydrate Sequence | 1 | 2015 | 20 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 138 | 0.130 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2015 | 24 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 179 | 0.130 |
Why?
|
| Triazoles | 1 | 2015 | 96 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 2271 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2016 | 292 | 0.130 |
Why?
|
| Peritoneal Neoplasms | 1 | 2016 | 177 | 0.130 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2014 | 6 | 0.130 |
Why?
|
| Exome | 1 | 2015 | 127 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2016 | 678 | 0.130 |
Why?
|
| Glycosylation | 1 | 2015 | 129 | 0.130 |
Why?
|
| Skull | 1 | 2016 | 249 | 0.130 |
Why?
|
| Anticoagulants | 2 | 2019 | 408 | 0.130 |
Why?
|
| Oligopeptides | 1 | 2015 | 179 | 0.130 |
Why?
|
| Plasma Cells | 1 | 2015 | 80 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 236 | 0.120 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 3030 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2014 | 46 | 0.120 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 23 | 0.120 |
Why?
|
| Asthma | 1 | 2022 | 955 | 0.120 |
Why?
|
| Risk Assessment | 4 | 2022 | 2261 | 0.120 |
Why?
|
| Protein Conformation | 2 | 2011 | 881 | 0.120 |
Why?
|
| Critical Illness | 1 | 2016 | 294 | 0.120 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2014 | 113 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2016 | 300 | 0.120 |
Why?
|
| DNA Repair | 2 | 2016 | 356 | 0.120 |
Why?
|
| Neurocalcin | 1 | 2013 | 2 | 0.120 |
Why?
|
| Adenosine Triphosphatases | 1 | 2014 | 153 | 0.120 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2013 | 23 | 0.120 |
Why?
|
| Inpatients | 1 | 2016 | 297 | 0.120 |
Why?
|
| Sex Factors | 1 | 2016 | 1054 | 0.120 |
Why?
|
| Citric Acid | 1 | 2013 | 38 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2014 | 155 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 853 | 0.110 |
Why?
|
| Cell Separation | 1 | 2013 | 196 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 329 | 0.110 |
Why?
|
| Isovaleryl-CoA Dehydrogenase | 3 | 2001 | 3 | 0.110 |
Why?
|
| Heparin | 1 | 2013 | 175 | 0.110 |
Why?
|
| DNA Damage | 1 | 2014 | 366 | 0.110 |
Why?
|
| Enzyme Stability | 3 | 2001 | 39 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2014 | 328 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2016 | 878 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1197 | 0.110 |
Why?
|
| Middle Aged | 4 | 2019 | 25028 | 0.100 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2014 | 276 | 0.100 |
Why?
|
| Pelvic Neoplasms | 1 | 2012 | 45 | 0.100 |
Why?
|
| Acetylation | 1 | 2011 | 121 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6509 | 0.100 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2014 | 434 | 0.100 |
Why?
|
| Ubiquitin | 1 | 2011 | 93 | 0.100 |
Why?
|
| Methylation | 1 | 2011 | 251 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 330 | 0.100 |
Why?
|
| Time Factors | 2 | 2016 | 5210 | 0.100 |
Why?
|
| Gene Expression | 1 | 2015 | 1284 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 1204 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 763 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2014 | 533 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1686 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 763 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 744 | 0.090 |
Why?
|
| Precision Medicine | 3 | 2021 | 395 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 736 | 0.090 |
Why?
|
| Cell Cycle | 1 | 2011 | 502 | 0.090 |
Why?
|
| Erythrocyte Transfusion | 1 | 2010 | 60 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 536 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2009 | 63 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2009 | 106 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2009 | 49 | 0.090 |
Why?
|
| Ecosystem | 2 | 2023 | 316 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 100 | 0.090 |
Why?
|
| Isoantibodies | 1 | 2010 | 114 | 0.090 |
Why?
|
| Apoptosis | 1 | 2015 | 1683 | 0.090 |
Why?
|
| Phosphorylation | 1 | 2011 | 1106 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2010 | 267 | 0.080 |
Why?
|
| Information Storage and Retrieval | 1 | 2009 | 120 | 0.080 |
Why?
|
| Cell Line | 2 | 2013 | 2468 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 188 | 0.080 |
Why?
|
| DNA, Neoplasm | 1 | 2009 | 265 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2009 | 143 | 0.080 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 131 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2022 | 2379 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2022 | 4213 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 387 | 0.080 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 1056 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2009 | 460 | 0.070 |
Why?
|
| Aged | 3 | 2019 | 18415 | 0.070 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2008 | 155 | 0.070 |
Why?
|
| Models, Molecular | 2 | 2001 | 1286 | 0.070 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 1074 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2013 | 1565 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2016 | 303 | 0.070 |
Why?
|
| Mice | 3 | 2016 | 11352 | 0.070 |
Why?
|
| Models, Biological | 1 | 2011 | 1749 | 0.060 |
Why?
|
| Genotype | 1 | 2009 | 1851 | 0.060 |
Why?
|
| Research Design | 1 | 2008 | 594 | 0.060 |
Why?
|
| Protein Binding | 2 | 2013 | 1456 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 70 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2022 | 131 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2001 | 1014 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 69 | 0.050 |
Why?
|
| Africa | 1 | 2022 | 98 | 0.050 |
Why?
|
| Energy Transfer | 1 | 2001 | 25 | 0.050 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2001 | 85 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 2360 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 1577 | 0.050 |
Why?
|
| Survival Rate | 2 | 2016 | 1863 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 335 | 0.050 |
Why?
|
| Mitotic Index | 1 | 2020 | 20 | 0.050 |
Why?
|
| Animals | 4 | 2016 | 26582 | 0.050 |
Why?
|
| Hemiterpenes | 1 | 2000 | 6 | 0.050 |
Why?
|
| Pentanoic Acids | 1 | 2000 | 6 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 339 | 0.050 |
Why?
|
| Leucine | 1 | 2000 | 67 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 266 | 0.050 |
Why?
|
| Mitosis | 1 | 2020 | 153 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2021 | 361 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 2000 | 117 | 0.050 |
Why?
|
| United States | 2 | 2023 | 6672 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 416 | 0.040 |
Why?
|
| Biological Transport | 1 | 2000 | 396 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 859 | 0.040 |
Why?
|
| Warfarin | 1 | 2019 | 103 | 0.040 |
Why?
|
| Binding Sites | 1 | 2001 | 1098 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 357 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2016 | 7993 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
| Durapatite | 1 | 2016 | 28 | 0.040 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2016 | 7 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2016 | 79 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2062 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2015 | 34 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2015 | 38 | 0.030 |
Why?
|
| Glutathione | 1 | 2016 | 104 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2015 | 51 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 150 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 677 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2022 | 8489 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 740 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 71 | 0.030 |
Why?
|
| International Cooperation | 1 | 2015 | 127 | 0.030 |
Why?
|
| Bortezomib | 1 | 2015 | 76 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2015 | 55 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 294 | 0.030 |
Why?
|
| Thalidomide | 1 | 2015 | 54 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1041 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 310 | 0.030 |
Why?
|
| DNA, Fungal | 1 | 2014 | 57 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 130 | 0.030 |
Why?
|
| Pyrazines | 1 | 2015 | 92 | 0.030 |
Why?
|
| Computer Security | 1 | 2014 | 16 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 17 | 0.030 |
Why?
|
| Information Systems | 1 | 2014 | 29 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 692 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 174 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 458 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2015 | 295 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 1718 | 0.030 |
Why?
|
| Confidentiality | 1 | 2014 | 78 | 0.030 |
Why?
|
| SEER Program | 1 | 2014 | 190 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 149 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2015 | 326 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2013 | 48 | 0.030 |
Why?
|
| Internet | 1 | 2015 | 312 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1805 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 363 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2013 | 281 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 280 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 486 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 1531 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2013 | 615 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 1137 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2013 | 579 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 532 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1673 | 0.020 |
Why?
|
| Laryngeal Edema | 1 | 2010 | 7 | 0.020 |
Why?
|
| Hemagglutinins | 1 | 2010 | 19 | 0.020 |
Why?
|
| Acute Chest Syndrome | 1 | 2010 | 16 | 0.020 |
Why?
|
| Death, Sudden | 1 | 2010 | 40 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 937 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 736 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 639 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 158 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 1379 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 293 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2232 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 2010 | 202 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 1156 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 3640 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 1458 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 916 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1565 | 0.020 |
Why?
|
| Pneumonia, Viral | 1 | 2010 | 316 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 2903 | 0.010 |
Why?
|
| Mitochondria, Liver | 1 | 1998 | 27 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1998 | 106 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 393 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 1998 | 485 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1998 | 526 | 0.010 |
Why?
|
| Kinetics | 1 | 1998 | 1513 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1998 | 1219 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1998 | 729 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1998 | 597 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1998 | 2818 | 0.010 |
Why?
|
| Rats | 1 | 1998 | 3990 | 0.010 |
Why?
|